000 04546nam a22006737a 4500
008 130913s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies
022 _a0002-9149
040 _aOvid MEDLINE(R)
099 _a22341925
245 _aSafety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
251 _aAmerican Journal of Cardiology. 109(9):1288-94, 2012 May 1.
252 _aAm J Cardiol. 109(9):1288-94, 2012 May 1.
253 _aThe American journal of cardiology
260 _c2012
260 _fFY2012
266 _d2013-09-17
501 _aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
520 _aData from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for >=1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates. Copyright 2012 Elsevier Inc. All rights reserved.
546 _aEnglish
650 _a*Angioplasty, Balloon, Coronary/mt [Methods]
_9952
650 _a*Coronary Artery Disease/th [Therapy]
_9171
650 _a*Drug-Eluting Stents
_9525
650 _a*Sirolimus/aa [Analogs & Derivatives]
_9674
650 _aAged
_92
650 _aAntineoplastic Agents, Phytogenic/pd [Pharmacology]
_9966
650 _aCoronary Angiography
_990
650 _aCoronary Artery Disease/ra [Radiography]
_991
650 _aCoronary Restenosis/pc [Prevention & Control]
_9967
650 _aFemale
_97
650 _aFollow-Up Studies
_9968
650 _aHumans
_911
650 _aImmunosuppressive Agents/pd [Pharmacology]
_9969
650 _aMale
_914
650 _aMiddle Aged
_915
650 _aPaclitaxel
_9970
650 _aProsthesis Design
_981
650 _aRetrospective Studies
_946
650 _aSirolimus/pd [Pharmacology]
_9971
650 _aTreatment Outcome
_918
651 _aMedStar Heart & Vascular Institute
657 _aComparative Study
657 _aJournal Article
657 _aRandomized Controlled Trial
657 _aResearch Support, Non-U.S. Gov't
700 _aBarbash, Israel M
_9965
700 _aBen-Dor, Itsik
_922
700 _aDvir, Danny
_923
700 _aKent, Kenneth M
_9135
700 _aMaluenda, Gabriel
_9286
700 _aPichard, Augusto D
_927
700 _aSatler, Lowell F
_929
700 _aSuddath, William O
_9139
700 _aTorguson, Rebecca
_9140
700 _aWaksman, Ron
_930
700 _aXue, Zhenyi
_9141
790 _aBarbash IM, Ben-Dor I, Dvir D, Kent KM, Maluenda G, Pichard AD, Satler LF, Suddath WO, Torguson R, Waksman R, Xue Z
856 _uhttp://dx.doi.org/10.1016/j.amjcard.2011.12.019
_zhttp://dx.doi.org/10.1016/j.amjcard.2011.12.019
942 _cART
_2z
_dArticle
999 _c1397
_d1397